Y-mAbs Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel antibody therapeutics for oncology targets based on a range of technologies licensed from Memorial Sloan Kettering Cancer Center under an exclusive world-wide and research collaboration agreement.
Neuroblastoma is a rare cancer that effects children, mostly under the age of 5 years old. It accounts for about 6% of all cancers in children. There are about 700 new cases of neurobastoma each year in the United States. The average age of children when they are diagnosed is about 1 to 2 years. Nearly 90% of cases are diagnosed by age 5. Neuroblastoma is very rare in people over the age of 10 years.
Neuroblastomas are cancers that start in early nerve cells (neuroblasts) of the sympathetic nervous system, so they can be found anywhere along this system. A little more than 1 out of 3 neuroblastomas start in the adrenal glands, about 1 out of 4 begin in sympathetic nerve ganglia in the abdomen. Most of the rest start in sympathetic ganglia near the spine in the chest or neck, or in the pelvis. [American Cancer Society 2018].
Ando manages outsourced bioassay development & validation and drives scientific discussions with the service provider. Additionally, Ando contributes to the optimisation of clinical study plans and supports Y-mAbs in regulatory submissions and handling of authority queries through close collaboration with the clinical and regulatory teams. Y-mAbs appreciates Ando´s know-how in bioanalytics and pharmacokinetics, its transparent and structured approach to solution finding and the quality of written documentation.